Aetna agreed to cover Abbott's neurostimulation pain therapy implant under a new national policy.
Here are five details:
1. Aetna's 22 million medical plan members will now have access to Proclaim, a dorsal root ganglion neurostimulation pain therapy implant. Abbott gained Proclaim through its acquisition of St. Jude Medical, MedTechDive reports.
2. Proclaim is designed to reduce pain by stopping signals passing from the dorsal root ganglion to the brain.
3. Aetna's decision will help Abbott deliver a return on its $25 billion St. Jude acquisition.
4. The FDA approved Proclaim in 2016, and the implant gained coverage from Medicare.
5. Researchers studied 152 people with complex regional pain syndrome or causalgia. After three months, 81 percent of patients who received Proclaim experienced at least a 50 percent reduction in pain, compared to about 55 percent of patients who received the control treatment.